Author(s):
Hariharan T, Dr. P.G. Sunitha, N. Deattu, Silambarasan D
Email(s):
hari965722@gmail.com
DOI:
10.52711/2231-5691.2026.00048 
Address:
Hariharan T1*, Dr. P.G. Sunitha2, N. Deattu3, Silambarasan D4
1Department of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Affiliated to The Tamil Nadu Dr. M.G.R Medical University, Chennai-600 003, Tamil Nadu, India.
2Assistant Professor, Department of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Affiliated to The Tamil Nadu, Dr. M.G.R Medical University, Chennai-600 003, Tamil Nadu, India.
3Assistant Professor, Department of Pharmaceutics, College of Pharmacy, Madras Medical College, Affiliated to The Tamil Nadu, Dr. M.G.R Medical University, Chennai-600 003, Tamil Nadu, India.
4JKKM – Annai JKKM Sampooraniammal College of Pharmacy, Affiliated to The Tamil Nadu, Dr. M.G.R Medical University, Komarapalayam, Namakkal, Tamil Nadu.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
This review article presents a comprehensive analysis of the various analytical methods developed for the quantitative estimation of Nefopam hydrochloride in bulk, pharmaceutical dosage forms and biological fluids. The focus is primarily on spectrophotometric and chromatographic techniques, including UV-Visible spectrophotometry, High Performance Liquid Chromatography (HPLC), High–Performance Thin-Layer Chromatography (HPTLC), HPLC-MS, and LC-MS/MS. Particular attention is given to the optimization of chromatographic parameters to ensure rapid, reliable, and cost-effective methodologies. An extensive survey of the literature from peer-reviewed pharmaceutical and analytical chemistry journals is undertaken to compare and evaluate the analytical approaches. This review aims to serve as a valuable resource for researchers and analysts seeking efficient and validated methods for the determination of Nefopam hydrochloride.
Cite this article:
Hariharan T, Dr. P.G. Sunitha, N. Deattu, Silambarasan D. A Comprehensive Review of Analytical Techniques for the Quantification of Nefopam Hydrochloride in Bulk, Pharmaceutical Formulations and Biological Fluids. Asian Journal of Pharmaceutical Research. 2026; 16(3):325-3. doi: 10.52711/2231-5691.2026.00048
Cite(Electronic):
Hariharan T, Dr. P.G. Sunitha, N. Deattu, Silambarasan D. A Comprehensive Review of Analytical Techniques for the Quantification of Nefopam Hydrochloride in Bulk, Pharmaceutical Formulations and Biological Fluids. Asian Journal of Pharmaceutical Research. 2026; 16(3):325-3. doi: 10.52711/2231-5691.2026.00048 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2026-16-3-16
REFERENCES:
1. Khobragade NH, Sheth DB, Patel CA, Beladiya J V., Patel S, Dalal M. Polycystic ovary syndrome: Insights into its prevalence, diagnosis, and management with special reference to gut microbial dysbiosis. Steroids. Elsevier Inc.; 2024. doi: 10.1016/ j.steroids.2024.109455 PubMed PMID: 38876407.
2. Christ JP, Cedars MI. Current Guidelines for Diagnosing PCOS. Diagnostics 2023, Vol 13, Page 1113. 2023 Mar 15; 13(6): 1113. doi:10.3390/DIAGNOSTICS13061113
3. Shen W, Qu Y, Jiang H, Wang H, Pan Y, Zhang Y, et al. Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis. Frontiers in Endocrinology. Frontiers Media S.A.; 2022. doi:10.3389/ fendo.2022.1051111
4. Wang T, Sha L, Li Y, Zhu L, Wang Z, Li K, et al. Dietary α-Linolenic Acid-Rich Flaxseed Oil Exerts Beneficial Effects on Polycystic Ovary Syndrome Through Sex Steroid Hormones—Microbiota—Inflammation Axis in Rats. Front Endocrinol (Lausanne). 2020 May 27; 11. doi:10.3389/fendo.2020.00284
5. Heydarpour F, Hemati N, Hadi A, Moradi S, Mohammadi E, Farzaei MH. Effects of cinnamon on controlling metabolic parameters of polycystic ovary syndrome: A systematic review and meta-analysis. Journal of Ethnopharmacology. Elsevier Ireland Ltd; 2020. doi: 10.1016/j.jep.2020.112741 PubMed PMID: 32151755.
6. Hooshmandi H, Ghadiri-Anari A, Ranjbar AM, Fallahzadeh H, Hosseinzadeh M, Nadjarzadeh A. Effects of licorice extract in combination with a low-calorie diet on obesity indices, glycemic indices, and lipid profiles in overweight/obese women with polycystic ovary syndrome (PCOS): a randomized, double-blind, placebo-controlled trial. J Ovarian Res. 2024 Dec 1; 17(1). doi:10.1186/s13048-024-01446-9 PubMed PMID: 39080737.
7. Liu L, Du B, Zhang H, Guo X, Zhou Z, Xiu A, et al. A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome. Chinese Medicine (United Kingdom). 2018 Aug 29; 13(1). doi:10.1186/s13020-018-0201-1
8. Li S, Wang T, Liu M, Ma T, Li Y, Liu J, et al. α-Linolenic Acid-Rich Flaxseed Oil Improves Polycystic Ovary Syndrome via Regulating Lipid Metabolism by GPR120-cAMP Pathway and Restoring Gut Microecology. Mol Nutr Food Res. 2025 Oct 1; 69(19). doi:10.1002/mnfr.70136 PubMed PMID: 40500964.
9. Wang T, Sha L, Li Y, Zhu L, Wang Z, Li K, et al. Dietary α-Linolenic Acid-Rich Flaxseed Oil Exerts Beneficial Effects on Polycystic Ovary Syndrome Through Sex Steroid Hormones—Microbiota—Inflammation Axis in Rats. Front Endocrinol (Lausanne). 2020 May 27; 11: 284. doi:10.3389/fendo.2020.00284
10. Szczuko M, Kikut J, Szczuko U, Szydłowska I, Nawrocka-Rutkowska J, Ziętek M, et al. Nutrition Strategy and Life Style in Polycystic Ovary Syndrome—Narrative Review. Nutrients 2021, Vol 13, Page 2452. 2021 Jul 18; 13(7): 2452. doi:10.3390/ nu13072452 PubMed PMID: 34371961.
11. Kocaoğlu M, Büyüknacar HS, Cevher A, Dağlıoğlu G, Kılıç Bağır E, Ertuğ FP, et al. Effects of a traditionally prepared Glycyrrhiza glabra root-based beverage on female reproductive function in rats. Front Nutr. 2025; 12: 1702655. doi:10.3389/fnut.2025.1702655 PubMed PMID: 41235307.
12. Graebin CS. The Pharmacological Activities of Glycyrrhizinic Acid (“Glycyrrhizin”) and Glycyrrhetinic Acid. Sweeteners. 2017; 245. doi:10.1007/978-3-319-27027-2_15
13. Semwal DK, Kumar A, Semwal RB, Dadhich NK, Chauhan A, Kumar V. Glycyrrhizin (Glycyrrhizic Acid)—Pharmacological Applications and Associated Molecular Mechanisms. Drugs and Drug Candidates. 2025 Sep 30; 4(4): 44. doi:10.3390/ddc4040044
14. Zheng L, Chen P fang, Dai W chao, Zheng Z qun, Wang H lan. Curcumin Alleviates Hyperandrogenism and Promotes Follicular Proliferation in Polycystic Ovary Syndrome Rats: Insights on IRS1/PI3K/GLUT4 and PTEN Modulations. Chin J Integr Med. 2022 Dec 1; 28(12): 1088–95. doi:10.1007/s11655-022-3582-z PubMed PMID: 36327049.
15. Chen D, Yu Q, Sheng S, Cai L, Zheng J, Zhang Y. Transcriptomic analysis of the effects exerted by curcumin on dihydrotestosterone-induced ovarian granulosa cells. Front Endocrinol (Lausanne). 2025; 16: 1522269. doi:10.3389/fendo.2025.1522269 PubMed PMID: 40017688.
16. Ji Z, Sang J, Wang H, Xia M, Hao T, Chen L, et al. Demethoxylation of curcumin enhances its inhibition on human and rat 17β-hydroxysteroid dehydrogenase 3: QSAR structure-activity relationship and in silico docking analysis. Food and Chemical Toxicology. 2024 Apr 1; 186: 114489. doi:10.1016/ j.fct.2024.114489 PubMed PMID: 38360388.
17. Guo J, Yan S, Jiang X, Su Z, Zhang F, Xie J, et al. Advances in pharmacological effects and mechanism of action of cinnamaldehyde. Front Pharmacol. 2024; 15: 1365949. doi:10.3389/fphar.2024.1365949 PubMed PMID: 38903995.
18. Maleki V, Faghfouri AH, Tabrizi FPF, Moludi J, Saleh-Ghadimi S, Jafari-Vayghan H, et al. Mechanistic and therapeutic insight into the effects of cinnamon in polycystic ovary syndrome: a systematic review. Journal of Ovarian Research 2021 14:1. 2021 Oct 9; 14(1): 130-. doi:10.1186/s13048-021-00870-5 PubMed PMID: 34627352.
19. Siddiqua A, Malik A, Niazi SG, Uttra AM, Mehmood MH, Munir M, et al. Cinnamaldehyde mitigates polycystic ovary syndrome pathologies by modulating NLRP3/NF-κB mediated inflammation using letrozole-induced model in female rats: a comprehensive in vitro, in vivo, in silico investigation. Naunyn-Schmiedeberg’s Archives of Pharmacology 2025. 2025 Aug 28;1–19. doi:10.1007/s00210-025-04536-7
20. Ikhtiyarova G, Музаффарова М.Х. THE ROLE OF DETERMINANT GENES OF STEROID HORMONES DYSFUNCTION REGULATORS (CYP17A1-RS743572, CYP19A1-RS247015) IN THE DEVELOPMENT OF PCOS IN WOMEN WITH INFERTILITY. Международный журнал научной педиатрии. 2022 Nov 30; (7): 05–11. doi:10.56121/2181-2926-2022-7-05-11
21. Rezgoun ML, El Khour D, Bendaoud H, Chellat D. CYP17A1 (rs74357) polymorphism and polycystic ovary syndrome risk: A systemic review and meta-analysis. Acta Biomedica. 2023 Aug 3; 94(4). doi:10.23750/abm. v94i4.14229 PubMed PMID: 37539608.
22. Kakuta H, Iguchi T, Sato T. The involvement of granulosa cells in the regulation by gonadotropins of Cyp17a1 in theca cells. In Vivo (Brooklyn). 2018 Nov 1; 32(6): 1387–401. doi:10.21873/ invivo.11391 PubMed PMID: 30348693.
23. Ikhtiyarova GA, Dustova NQ, Oripova FS, Tosheva II, Olimova NI, Qurbonova ZS. PCOS in women with infertility and role of determinant genes of steroid hormones. In: BIO Web of Conferences. EDP Sciences; 2024. doi:10.1051/bioconf/ 202412104008
24. Xing C, Zhao H, Zhang J, He B. The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility: A Systematic Review and Meta-Analysis. Frontiers in Physiology. Frontiers Media S.A.; 2022. doi:10.3389/fphys.2022.741285
25. Stueve TR, Wolff MS, Pajak A, Teitelbaum SL, Chen J. CYP19A1 promoter methylation in saliva associated with milestones of pubertal timing in urban girls. BMC Pediatr. 2014 Mar 20; 14(1). doi:10.1186/1471-2431-14-78 PubMed PMID: 24649863.
26. Hashemain Z, Amiri-Yekta A, Khosravifar M, Alvandian F, Shahhosseini M, Hosseinkhani S, et al. CYP19A1 Promoters Activity in Human Granulosa Cells: A Comparison between PCOS and Normal Subjects. Cell J. 2022 Apr 1; 24(4): 170–5. doi:10.22074/cellj.2022.7787
27. Hosseini E, Shahhoseini M, Afsharian P, Karimian L, Ashrafi M, Mehraein F, et al. Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome. Archives of Medical Science. 2019; 15(4): 887–95. doi:10.5114/ aoms.2019.86060
28. Zhang H, Fang J, Liu Y, Zhu W, Xu Y, Zhang Y, et al. Hsa_circ_0043532 contributes to PCOS through upregulation of CYP19A1 by acting as a ceRNA for hsa-miR-1270. J Ovarian Res. 2024 Dec 1; 17(1). doi:10.1186/s13048-024-01474-5 PubMed PMID: 39039600.
29. Tao P, Yan X, Wang Z. Mechanistic role of the KRTAP5-AS1/miR-199b-5p/CYP19A1 axis in polycystic ovary syndrome pathogenesis. Journal of Ovarian Research. 2025 Dec 1; 18(1). doi:10.1186/s13048-025-01746-8 PubMed PMID: 40781325.
30. Junnila A, Petruk N, Heikelä H, Postila P, Hakkarainen J, Martinez-Nieto G, et al. Female Mice with HSD17B1 Inactivation Show Mild Hyperandrogenism without Notable Impact on Reproductive Function or Bone. Endocrinology (United States). 2026 Jan 1; 167(1). doi:10.1210/endocr/bqaf167 PubMed PMID: 41219171.
31. Li J, Zhang S, Shen C, Niu Z, Yang H, Zhang K, et al. Indel mutations within the bovine HSD17B3 gene are significantly associated with ovary morphological traits and mature follicle number. J Steroid Biochem Mol Biol. 2021 May 1; 209: 105833. doi:10.1016/j.jsbmb.2021.105833 PubMed PMID: 33524543.
32. Hossain MA, Al Ashik SA, Mahin MR, Al Amin M, Rahman MH, Khan MA, et al. Systems biology and in silico-based analysis of PCOS revealed the risk of metabolic disorders. Heliyon. 2022 Dec 1; 8(12): e12480. doi:10.1016/J.HELIYON.2022.E12480
33. Guan H ru, Li B, Zhang Z hua, Wu H song, He X lishang, Dong Y jie, et al. Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome. BMC Complement Med Ther. 2023 Dec 1; 23(1): 1–21. doi:10.1186/S12906-023-04280-6/FIGURES/10 PubMed PMID: 38102584.
34. Huang H, He Y, Li W, Wei W, Li Y, Xie R, et al. Identification of polycystic ovary syndrome potential drug targets based on pathobiological similarity in the protein-protein interaction network. Oncotarget. 2016; 7(25): 37906. doi:10.18632/ ONCOTARGET.9353 PubMed PMID: 27191267.
35. Khan MJ, Ullah A, Basit S. Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives. Appl Clin Genet. 2019; 12: 249. doi:10.2147/TACG.S200341 PubMed PMID: 31920361.
36. Gao P, Hu Y, Wang J, Ni Y, Zhu Z, Wang H, et al. Underlying Mechanism of Insulin Resistance: A Bioinformatics Analysis Based on Validated Related-Genes from Public Disease Databases. Med Sci Monit. 2020;26. doi:10.12659/MSM.924334 PubMed PMID: 32651353.
37. Mosharaf MP, Kibria MK, Hossen MB, Islam MA, Reza MS, Mahumud RA, et al. Meta-Data Analysis to Explore the Hub of the Hub-Genes That Influence SARS-CoV-2 Infections Highlighting Their Pathogenetic Processes and Drugs Repurposing. Vaccines (Basel). 2022 Aug 1; 10(8): 1248. doi:10.3390/ VACCINES10081248/S1
38. Xu W, Tang M, Wang J, Wang L. Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology. Evidence-Based Complementary and Alternative Medicine. 2020 Jan 1; 2020(1): 4086864. doi:10.1155/2020/ 4086864
39. Heidarzadehpilehrood R, Pirhoushiaran M, Abdollahzadeh R, Osman MB, Sakinah M, Nordin N, et al. A Review on CYP11A1, CYP17A1, and CYP19A1 Polymorphism Studies: Candidate Susceptibility Genes for Polycystic Ovary Syndrome (PCOS) and Infertility. Genes (Basel). 2022 Feb 5; 13(2): 302–302. doi:10.3390/GENES13020302 PubMed PMID: 35205347.
40. Kaur R, Kaur T, Kaur A. Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. J Assist Reprod Genet. 2018 Jun 1; 35(6): 1123. doi:10.1007/S10815-018-1162-0 PubMed PMID: 29564739.
41. Rezgoun ML, El Khour D, Bendaoud H, Chellat D. CYP17A1 (rs74357) polymorphism and polycystic ovary syndrome risk: A systemic review and meta-analysis. Acta Bio Medica: Atenei Parmensis. 2023 Aug 3; 94(4): e2023167. doi:10.23750/ ABM.V94I4.14229 PubMed PMID: 37539608.
42. Gowtham Kumar G, Paul SFD, Molia C, Manickavasagam M, Ramya R, Usha Rani G, et al. The association between CYP17A1, CYP19A1, and HSD17B1 gene polymorphisms of estrogen synthesis pathway and ovarian cancer predisposition. Meta Gene. 2022 Feb 1; 31: 100985. doi: 10.1016/J.MGENE.2021.100985
43. Hai B, Zhang Y, Huang J, Mprah R, Wang M. Exploring the key ingredients and mechanisms of Banxia Xiexin decoction for the treatment of polycystic ovary syndrome based on network pharmacology and experimental validation. Ann Med. 2025; 57(1). doi:10.1080/07853890.2025.2503921 PubMed PMID: 40375680.
44. Li X, Ma J, Guo L, Dong C, Zhu G, Hong W, et al. Identification of Bioactive Compounds and Potential Mechanisms of Kuntai Capsule in the Treatment of Polycystic Ovary Syndrome by Integrating Network Pharmacology and Bioinformatics. Oxid Med Cell Longev. 2022; 2022. doi:10.1155/2022/3145938 PubMed PMID: 35528524.
45. Xu W, Tang M, Wang J, Wang L. Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology. Evidence-based Complementary and Alternative Medicine. 2020; 2020. doi:10.1155/2020/4086864
46. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 Oct 1; 37(5): 467–520. doi:10.1210/ER.2015-1104 PubMed PMID: 27459230.
47. Zhu L, Li Z, Dong J. Application of Network Pharmacology, Computational Molecular Docking and Experimental Techniques to Study the Anticancer Effects of Ursolic Acid on Oral Squamous Carcinoma Cells. Indian Journal of Pharmaceutical Education and Research. 2025 Apr 1; 59(2): 826–40. doi:10.5530/ijper.20250379
48. Matte S, Wanjari M, Nalban N, Tamboli M, Jamadagni P, Bagde V, et al. Pharmacological mechanisms of Glycyrrhiza glabra in peptic ulcer: a systems biology and experimental approach. In Silico Pharmacol. 2025 Oct 17; 13(3): 156. doi:10.1007/s40203-025-00429-y